Profit up 80% at Dechra, Chesire vet drug giant

Chesire-based veterinary drugs giant Dechra Pharmaceuticals said on Monday its revenue rose 21.8% to £299.8 million and reported profit before tax soared more than 80% to £35.4 million in the six months ended December 31, 2020.

Interim dividend has been increased by 8% to 11.11p per share.

In its outlook, Dechra said: “Trading in the second half remains robust, although we are starting to see the pre-Brexit inventory build unwind and, therefore, we expect the balance of trading to be first half weighted.

“Overall the outlook for the full year remains positive and in line with our January trading update.

“We expect the strong favourable market conditions to remain, our recent acquisitions to perform well and our supply chain improvement to continue.”

Dechra CEO Ian Page said: “Despite 2020 being one of the most challenging years in Dechra’s history, it is pleasing to report that the calendar year ended strongly resulting in an excellent performance in the first half of our financial year.”

 

About the Author

Mark McSherry
Dalriada Media LLC sites are edited by veteran news journalist Mark McSherry, a former staff editor and reporter with Reuters, Bloomberg and major newspapers including the South China Morning Post, London's Sunday Times and The Scotsman. McSherry's journalism has also appeared in The Washington Post, The Guardian, The Independent, The New York Times, London's Evening Standard and Forbes. McSherry is also a professor of journalism and communication arts in universities and colleges in New York City. Scottish-born McSherry has an MBA from the University of Edinburgh and a Certificate in Global Affairs from New York University.